Showing results (101-110 of 301) with videos related to
Sort By:
Pageof 31
Blood|August 28, 2009
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomasEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.Plos One|May 23, 2013
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cellsDonglin Liu, Chien-Hsing Chang, Edmund A Rossi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)M Jules Mattes, Robert M Sharkey, Habibe Karacay, et al.Journal of Labelled Compounds & Radiopharmaceuticals|January 11, 2014
Al(18) F labeling of peptides and proteinsPeter Laverman, William J McBride, Robert M Sharkey, et al.Seminars in Nuclear Medicine|March 31, 2010
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapyRobert M Sharkey, Edmund A Rossi, William J McBride, et al.EJNMMI Research|December 13, 2019
Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer modelsFortuné M K Elekonawo, Desirée L Bos, David M Goldenberg, et al.Molecular Cancer Therapeutics|May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric CancersChien-Hsing Chang, Yang Wang, Maria Zalath, et al.Oncotarget|June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugatesSerengulam V Govindan, Thomas M Cardillo, Sung-Ju Moon, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.Pageof 31